Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms

Ann Rheum Dis. 2018 Jul;77(7):e39. doi: 10.1136/annrheumdis-2017-212251. Epub 2017 Sep 6.

Authors

Jean-Yves L Reginster¹, Olivier Bruyere², Cyrus Cooper^{3

4}

Affiliations

¹ Department of Public Health, Epidemiology and Health Economics, University of Liège, Liege, Belgium.
² Department of Public Health and Epidemiology, University of Liege, Liege, Belgium.
³ MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
⁴ NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.

PMID: 28877867
DOI: 10.1136/annrheumdis-2017-212251

No abstract available

Keywords: knee osteoarthritis; osteoarthritis; treatment.

Publication types

Letter
Comment

MeSH terms

Glucosamine
Humans
Knee Joint
Osteoarthritis, Hip*
Osteoarthritis, Knee*

Substances

Glucosamine

Grants and funding